Indeed, in vivo studies of gefitinib have shown that although there was an effect on dephosphorylating EGFR in amplified tumours, there was no demonstrable effect on EGFR pathway activity, highlighting mechanisms for resistance that are independent of direct EGFR pathway activation [6]. This evidence concerns the gene EGFR and neoplasm.